Impact of Trump's Drug Price Reduction Plan on Indian Pharmaceutical Companies

this is part 3 read all parts for full details 3. Risk of Market Access Loss Failure to meet MFN pricing conditions could result in exclusion from Medicare. Given that Medicare accounts for a significant volume of prescriptions, losing access would materially affect sales volumes, especially for chronic disease treatments. 4. Tariff and Geopolitical Risks Trump has also indicated a willingness to impose tariffs on pharmaceutical imports from countries like India and China. If enforced, tariffs would inflate operational costs and force Indian exporters to either absorb the costs or lose pricing competitiveness. Companies may explore expanding sales in other regions like Europe, Latin America, and Southeast Asia to offset potential volume loss in the U.S. 5. Strategic Response and Business Realignment To navigate this evolving landscape, Indian pharmaceutical companies will likely pursue several strategies: • Increasing operational efficiency through cost rationalization and automation. • Prioritizing the development of complex generics and biosimilars that offer better pricing power. Conclusion Trump’s revived Most Favored Nation pricing plan is a potential game-changer for Indian pharmaceutical companies with deep exposure to the U.S. market. While it could bring relief to U.S. consumers, it places Indian exporters in a challenging position, facing reduced prices, tighter margins, and potential access restrictions. Sun Pharma, Cipla, Lupin, Aurobindo, and Dr. Reddy’s will need to adapt swiftly through operational, regulatory, and geographic diversification. As the policy framework evolves and legal challenges surface, Indian pharma companies must remain agile, balancing innovation and cost-efficiency to sustain their foothold in the world’s largest pharmaceutical market. This report has been independently researched and curated by Adarsh Nimborkar, Investment Advisor and Market Analyst. SEBI Registration No: INA000019789